{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Foresee+Pharmaceuticals+Co.%2C+Ltd.",
    "query": {
      "sponsor": "Foresee Pharmaceuticals Co., Ltd."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T21:49:27.180Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05493709",
      "title": "Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Puberty; Precocious, Central"
      ],
      "interventions": [
        {
          "name": "Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Foresee Pharmaceuticals Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "9 Years",
        "sex": "ALL",
        "summary": "2 Years to 9 Years"
      },
      "enrollment_count": 94,
      "start_date": "2023-06-02",
      "completion_date": "2026-05-24",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-10-08T21:49:27.180Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • San Diego, California • Jacksonville, Florida + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05493709"
    },
    {
      "nct_id": "NCT02712320",
      "title": "Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "LMIS 50 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Foresee Pharmaceuticals Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2016-02",
      "completion_date": "2017-12-19",
      "has_results": true,
      "last_update_posted_date": "2019-03-26",
      "last_synced_at": "2026-10-08T21:49:27.180Z",
      "location_count": 7,
      "location_summary": "Homewood, Alabama • San Diego, California • Meridian, Idaho + 4 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Lawrenceville",
          "state": "New Jersey"
        },
        {
          "city": "Concord",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02712320"
    },
    {
      "nct_id": "NCT02234115",
      "title": "Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Leuprolide Mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Foresee Pharmaceuticals Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 137,
      "start_date": "2014-08",
      "completion_date": "2017-01-05",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-10-08T21:49:27.180Z",
      "location_count": 8,
      "location_summary": "Homewood, Alabama • Laguna Hills, California • San Diego, California + 5 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Lawrenceville",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02234115"
    },
    {
      "nct_id": "NCT03261999",
      "title": "Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Leuprolide Mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Foresee Pharmaceuticals Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 144,
      "start_date": "2017-09-26",
      "completion_date": "2019-02-01",
      "has_results": true,
      "last_update_posted_date": "2020-05-04",
      "last_synced_at": "2026-10-08T21:49:27.180Z",
      "location_count": 6,
      "location_summary": "Homewood, Alabama • Tucson, Arizona • Denver, Colorado + 3 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Concord",
          "state": "North Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03261999"
    },
    {
      "nct_id": "NCT04750278",
      "title": "A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Severe to Critical COVID 19 With Associated ARDS"
      ],
      "interventions": [
        {
          "name": "FP-025 100 mg",
          "type": "DRUG"
        },
        {
          "name": "FP-025 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Foresee Pharmaceuticals Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2021-04-06",
      "completion_date": "2022-04-18",
      "has_results": true,
      "last_update_posted_date": "2024-01-05",
      "last_synced_at": "2026-10-08T21:49:27.180Z",
      "location_count": 8,
      "location_summary": "Chula Vista, California • La Mesa, California • Rockville, Maryland + 4 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Minto",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04750278"
    }
  ]
}